Fig. 6.
(A) Schematic illustration of TA-siRNA nanogel synthesis and their dual therapeutic action. (B) TA in the PHTB(TA-siRNA) hydrogel effectively reduces ROS levels in diabetic chronic wounds, as compared to the control groups. (C) The M2/M1 macrophage ratio in the ES therapy–PHTB(TA-siRNA) hydrogel groups was significantly higher than in the other groups. (D) Mechanism of siRNA release from TA-siRNA nanogels [168]. Copyright 2022, Wiley-VCH GmbH.
